4Lehnet M. Clinical multidrug resistance in cancer:A multifactorial problem[J]. Eur J Cancer, 1996,32A:912.
5Aros S, Suwa H,Mandai M,et al. Expression of multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer[J]. Cancer Res, 1994,43:1355-1358.
6McClay EF, McClay MET, Albright K, et al. Tamoxifen modulation of cisplatin resistance in patients with metastatic melanoma[J].Cancer, 1994,72:1914.
7Zhang X, Wang JF, Chandran B, et al. Kaposis sarcoma-associated herpesvirus activation of vascular endothelial growth factor receptor 3 alters endothelial function and enhances infection[J]. J Biol Chem, 2005, 280(28) ..26216-26224.
8Gorge A. Clinical Studies with modulation of multidrug resistance[J]. HematolOncolClin North Am,2009,9(2):363 368.
9Col SPC, Chanda ER, Dicke FP, et al. Non-P-glycoprotein-mediatedmultidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II [J]. Cancer Res, 2007, 51(13) :3345-3352.
10Campos L, Guyo D, Archimband E, et al. Clinical signicance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leakemia cellsat diagnosis[J]. Blood, 2010, 79 (2) : 473-476.
